Cinitapride

Research use only, not for human use.

Cinitapride is a gastroprokinetic agent. It slows the actions of the muscles to reduce the symptoms of conditions such as acid reflux, delayed gastric emptying, and ulcer dyspepsia.

Cinitapride is a gastroprokinetic agent. It slows the actions of the muscles to reduce the symptoms of conditions such as acid reflux, delayed gastric emptying, and ulcer dyspepsia. Cinitapride acts as an antagonist of the 5-HT2 receptors and as an agonist of the 5-HT1 and 5-HT4 receptors.

——

Cinitapride (intraperitoneal injection; 0.25-1 mg/kg; once) shows gastroprotective effetcs in gastric ulceration rat model. Animal Model:Male Wistar rats with gastric ulcerationDosage:0.25-1 mg/kg Administration:Intraperitoneal injection; 0.25-1 mg/kg; once Result:Reduced haemorrhagic lesions compared with the ulcerated control group.Decreased the percentage of ulceration to 28.76% at the highest dose (1 mg/kg).Attenuated the increase myeloperoxidase activity (p<0.05, p<0.01).Increased GSH-px activity in the gastric mucosa.

Cidine | Blaston | Cinmove | Cintapro | Paxapride | cinitapride tartrate

Endocrinology/Hormones

5-HT Receptor

——

——

——

66564-14-5

402.495

C21H30N4O4

>98% (HPLC)

In Vitro:?DMSO : 20.83 mg/mL (51.75 mM)

CCOc1cc(N)c(cc1C(=O)NC1CCN(CC2CCC=CC2)CC1)[N+]([O-])=O

——

(-20℃)

With Ice Pack

≥ 2 years